analysis. The first, and perhaps most important, step in the analysis process is the initial screening of biological specimens for illicit, medically prescribed, and over-the-counter compounds that may be present and potentially be a cause and/or factor in the accident. Currently, our general unknown screening (GUS) procedure involves, in part, both gas chromatography-mass spectrometry (GC-MS) and liquid chromatography (LC) with both diode-array detection (DAD) and fluorescence detection. Both GC and LC techniques have inherent limitations that prevent the detection of certain types of compounds. The decreased specificity and sensitivity of LC-DAD has been an impediment to the existing GUS procedure. Therefore, our laboratory set out to develop and validate an LC-MS-MS procedure that is superior to LC-DAD. The limits of detection of 359 forensically important xenobiotics have been established following solid-phase extraction from whole blood and analysis by LC-MS-MS. Although whole blood was used as the matrix during instrument validation, the method has been successfully applied to both forensic urine and tissue specimens as well.
Introduction
Procedures utilized for the initial detection of xenobiotic compounds in a biological sample, usually referred to as general unknown screening (GUS), employ a variety of analytical techniques (1) . GUS can involve various immunoassay methodologies, including radioimmunoassay (RIA), fluorescence polarization immunoassay (FPIA), and enzyme-linked immunosorbent assay (ELISA) (2) . These immunoassay techniques are ideal for the detection of compounds in different drug classes like various drugs of abuse or widely prescribed pharmaceuticals such as oxycodone; however, these techniques are restricted to a specific and limited list of compounds. This limitation forces most laboratories to incorporate additional layers of analytical instrumentation and testing into the GUS procedure so that a wider variety of compounds may be detected. These chromatographic techniques can be coupled to a variety of detectors such as mass spectrometers (MS), fluorescence, or ultraviolet (UV) diode-array (DAD). Gas chromatography (GC)-MS has been utilized in the GUS process for decades (3) (4) (5) . This technique is extremely useful because of the availability of large libraries containing hundreds of thousands of standardized spectra. However, GC-MS also has limitations. For example, large molecules that are thermally labile are not volatile enough to be amenable to this technique. As pharmaceutical compounds become larger and more complex, this issue has become more prevalent. One viable solution to this problem is the addition of another analytical technique, liquid chromatography (LC), to the GUS procedure. LC has been used for decades as well, and it is specifically suited for the separation of large, thermally labile compounds (5) . The most common detector used in conjunction with LC is the DAD. DADs provide UV spectra for compounds that absorb UV radiation. These spectra are generally compound-dependent and can be placed in a library for identifying unknown compounds in a specimen. However, DAD spectra are not as specific as MS (5) . One study demonstrated that only 60% of the compounds in an LC-UV library could be identified by UV spectra alone (6) . Numerous compounds may have spectra that look similar, making identification tedious. Furthermore, this method of detection cannot identify compounds that exhibit no UV absorbance.
In recent years, the combination of LC and MS has become increasingly prevalent in many laboratories (1, 5, (7) (8) (9) (10) (11) (12) . Recent work has described the development of a linear ion-trap LC-MS screening method that focused on pesticides extracted from blood specimens (13) , and other published methods have described the use of hybrid, triple-quadrupole/ion-trap instruments, as screening tools (14, 15) . The combination of LC and MS provides a nearly universal separation technique with the most sensitive and specific detector, allowing for the detection of a wider variety of compounds than either GC-MS or LC-DAD alone. LC-MS will play a significant role in the future of specimen screening. Laboratories around the world have begun the process of phasing out LC-UV and replacing it with LC-MS methodology. Our laboratory created and validated an ion-trap LC-MS-MS method and an associated library of compounds for use as a part of our GUS procedure, which is presented here.
Materials and Methods

Reagents, standards, and supplies
All aqueous solutions were prepared using double deionized water (DDW), which was obtained using an ELGA, Purelab Ultra water system (ELGA, Lowell, MA). All chemicals were purchased in the highest possible purity and used without any further purification. All solvents, including acetonitrile, methanol, ethyl acetate, methylene chloride, and hexane, were purchased in the highest possible grade and were obtained from Fisher Scientific (Fair Lawn, NJ). Formic acid (97%) and ammonium formate were purchased from ICN (ICN Biomedicals, Irvine, CA) and Fisher Scientific, respectively. Analytical grade compound standards were obtained from a variety of commercial sources as either 1 mg/mL liquid standards or pure powder standards. When analytical-grade standards were not commercially available, drug standards were obtained via prescription. Pills were purchased, crushed, filtered, and diluted, resulting in solutions that were approximately 1 mg/mL for the compounds of interest.
Instrumentation
Analyte separation was achieved using a Agilent 1200 series HPLC (Agilent, Wilmington, DE) equipped with a Security Guard™ C-8 guard column (4.0 × 3.0-mm i.d., 3-µm particles) from Phenomenex ® (Torrance, CA), followed immediately by a Hypersil Gold PFP (150 × 2.1-mm i.d., 5-µm particles) analytical column obtained from ThermoFisher Scientific (San Jose, CA). Samples were injected using an Agilent G1367C autosampler. Identification and quantification were accomplished using a ThermoFisher Scientific model LTQ XL electrospray ionization (ESI) linear ion-trap MS that utilized nitrogen as the sheath and auxiliary gas.
For all determinations, the HPLC was operated in a gradient mode with a constant flow rate of 0.30 mL/min. The mobile phase employed consisted of acetonitrile with 0.10% formic acid (A) and 10 mM ammonium formate buffer with 0.10% formic acid (B). The gradual gradient was set up as follows: initially, 5% A 95% B; at 5.0 min, 45% A 55% B; at 18 min 70% A 30% B; at 20 min 95% A 5% B; at 25 min 95% A 5% B; at 25.1 min 5% A 95% B; and at 30 min 5% A 95% B. This resulted in a total run time of 30 min. Of particular note is the 4.9 min equilibration time (25.1-30 min) at the end of the gradient sequence to ready the column for the next injection. The sample injection volume was held constant at 10 µL. The HPLC column was routinely allowed to equilibrate overnight prior to use. Following use, the column was washed with and stored in 50:50 acetonitrile/H 2 O.
Operating conditions for the data collection segments of the MS were as follows: heated capillary temperature, 350°C; capillary voltage, 4.00 V; source current, 4.00 µA; sheath gas flow (nitrogen), 25; auxiliary gas flow (nitrogen) 5; spray voltage, 5.00 kV; multipole 00 offset, -3.25 V; lens 0 voltage, -5.50 V; multipole 0 offset, -5.25 V; lens 1 voltage, -8.00 V; gate lens voltage, -56.00 V; multiplier 1 offset, -11.50 V; multipole RF amplitude, 400 V; front lens, -5.75 V; and 1 microscan having a maximum ion injection time of 100 ms. This segment was further split into 9 separate scan events, 6 dedicated to compounds that ionized in the positive mode and 3 dedicated to compounds that ionized in the negative mode. More scan events were included for positively ionizing compounds because the precursor mass list for these drugs was significantly larger, and therefore, the possibility of co-eluting compounds was increased. Scan event 1 collected full-scan data in the positive ion mode. Scan events 2-6 were data-dependent scans that collected MS-MS data following fragmentation of any ion from the positive-ion precursor mass list that was encountered in scan event 1. Collision-induced dissociation (CID) of the precursor ions encountered from the positive-ion mass list using a collision energy of 35% produced MS-MS spectra that were compared to those in the library. Scan event 7 collected full-scan data in the negative ion mode. Scan events 8-9 were data-dependent scans that collected MS-MS data following fragmentation of any ion from the negative-ion precursor mass list that was encountered in scan event 7. Total scan time varied throughout the run. Scan events 1 and 7 were constant and allowed 200 ms each. All other scan events were data-dependent and only occurred if a precursor ion in the mass list was encountered; however, each was allowed 100 ms when used. If all nine scan events were used at any one time, the total scan time would have been 1.1 s. For method development purposes, no ion exclusion list was created or employed either prior to or during the run. However, this option is available to the user if desired.
Initially, precursor ions were identified for each compound investigated by infusing the analyte directly into the mobile phase, which was then introduced into the MS at a flow rate of 0.30 mL/min. Following either [M+H] + or [M-H] -ion identification, the precursor ions were added to the appropriate mass list (positive or negative). Fragmentation at a collision energy of 35% provided an MS-MS spectra for each analyte of interest that was exported into the newly created library. Finally, retention times for each analyte were obtained through the injection of neat standards: 1 µL of a 10 µg/mL standard was injected onto the LC column under the conditions described. This provided the retention time data that were then added to the MS method, creating a retention time range in which the MS would target a particular precursor ions.
Control of the HPLC system, integration of any chromatographic peaks, and communication with the MS were accomplished via a personal computer using Xcalibur™ LC-MS software (ThermoFisher Scientific). Unknown identification and report processing was accomplished using ToxID™ version 1.0 software (ThermoFisher). Criteria for reporting a presumptive positive included search index and reverse search index, which are spectral matching algorithms defined within the software that compared the acquired spectrum with the spectrum in the library, a retention time comparison between expected and actual, and the precursor ion's mass-to-charge ratio.
Sample extraction
Locally obtained bovine whole blood was used to prepare all controls, which were extracted in the following manner. Compounds were analyzed in groups of 10 and were selected to minimize the occurrence of co-elution as often as possible. Each group of compounds was prepared and analyzed at four different concentrations (1, 10, 100, and 1000 ng/mL), which provided an approximation of the limit of detection (LOD) for each compound. The 1000 ng/mL control concentration was prepared by first diluting 100 µL of each 1 mg/mL stock standard to 10 mL in a class A volumetric flask with DDW, providing an aqueous 10 µg/mL working solution. One milliliter of the 10 µg/mL working solution was diluted to 10 mL in a class-A volumetric flask with bovine whole blood, resulting in a 1000 ng/mL whole blood control. The 1000 ng/mL control was diluted by serial dilution using bovine whole blood as the diluent to create the remaining control specimens at concentrations of 100, 10, and 1 ng/mL. Following data analysis, some individual compounds were re-extracted at concentrations between these values (e.g., 5 ng/mL). This step was taken, for example, when a compound showed a strong response at 10 ng/mL followed by no response at 1 ng/mL.
Three-milliliter aliquots of each control specimen were transferred to individual 15-mL screw-top vials. Each of the internal standard compounds we currently use in our GC-MS and LC-UV screening procedures was added to each tube in this study. One-hundred nanograms of each compound was added as 100-µL aliquots of a 1000 ng/mL working solution. These compounds included amphetamine-d 8 , methamphetamine-d 8 , medazepam, and SERTIS. SERTIS is an acronym for sertraline internal standard, a sertraline compound with two bromine atoms substituted for chlorine atoms. This molecule is synthesized specifically for use as an internal standard. Following internal standard addition, 6 mL of 0.10 M phosphate buffer, pH 6.00, was added to each specimen. The mixture was then placed on a rotary mixing wheel and mixed for 15 min by simple rotation of the wheel at 15 rpm. Centrifugation at 2500 × g for 30 min allowed for the removal of cellular debris and proteins. Following centrifugation, the extracts were transferred to Bond Elute Certify ® solid-phase extraction (SPE) columns obtained from Varian (Harbor City, CA.) for the isolation of any basic compounds. The columns had been pre-conditioned with 2.00 mL methanol, followed by 2.00 mL 0.10 M phosphate buffer (pH 6.00). Care was taken not to dry the column prior to adding the extract. Column flow rates of 1-2 mL/min were maintained in each SPE step using a Varian 24-port Cerex™ SPE) with a nitrogen pressure of 3 psi. Once each sample had passed through its respective column, the columns were washed with 1.00 mL of 1.00 M acetic acid, and then dried completely with 25 psi nitrogen for 5 min. The columns were then washed with 6.00 mL of methanol. The methanol wash was collected in clean, labeled 10 × 100-mm culture tubes. This wash contained any acidic or neutral compounds that may have been present in the sample. Following collection of the methanol wash, the columns were again dried completely with 25 psi nitrogen for 5 min. The basic analytes were eluted from the Bond Elute Certify columns with 3.00 mL of 2.0% ammonium hydroxide in ethyl acetate, which was prepared each day.
The previously collected methanol wash was evaporated to dryness in a TurboVap ® concentration workstation (Caliper Life Sciences, Hopkinton, MA) set at 40°C under a stream of dry nitrogen. Once dry, the contents of each tube were reconstituted with 3 mL of 0.10 M phosphate buffer (pH 6.00), vortex mixed, and transferred to Styre Screen SPE columns (United Chemical Technologies, Bristol, PA), which had been preconditioned with 2.00 mL methanol, followed by 2.00 mL 0.10 M phosphate buffer (pH 6.00). Care was taken not to dry the SPE column prior to extract addition. Column flow rates of 1-2 mL/min were maintained in each step using a Varian 24-port Cerex SPE processor with a nitrogen pressure of 1 psi. As each sample passed through its respective column, the columns were washed with 2 mL 0.10 M phosphate buffer, pH 6.00, and then dried completely with 25 psi nitrogen for 1 min. The columns were then washed by adding 1 mL of 1.0 M acetic acid, dried completely with 25 psi nitrogen for 2 min, washed by adding 2 mL of hexane, and again dried completely with 25 psi nitrogen for 2 min. The acidic and neutral analytes were eluted from the UCT Styre Screen columns with 3 mL of methylene chloride.
Eluents from both SPE extractions were evaporated to dryness in a TurboVap set at 40°C under a stream of dry nitrogen. Once dry, the contents of each tube were reconstituted in 50 µL of 50:50 acetonitrile/water. The two eluents from each sample were then transferred to separate LC-MS vials for analysis, resulting in an acid/neutral and a base vial from each specimen.
Results and Discussion
This study established the LODs for 359 forensically valuable compounds in the newly created ion-trap LC-MS-MS library while also establishing the appropriate precursor and product ion for each compound and in which fraction (basic or acid/neutral) each compound should be expected following this extraction procedure. Acquisition of the mass spectra was achieved using a ThermoFisher Scientific LTQ XL linear iontrap with an Ion Max™ ESI source in both positive and negative † All concentrations are presented with the units of ng/mL. ‡ Denotes the fraction from which the compound was recovered during the extraction process. If seen in significant quantities in both fractions, the proportion is given followed by (A) for the acid and (B) for the base fraction. † All concentrations are presented with the units of ng/mL. ‡ Denotes the fraction from which the compound was recovered during the extraction process. If seen in significant quantities in both fractions, the proportion is given followed by (A) for the acid and (B) for the base fraction. ionization modes within a single run. Full-scan data were collected throughout each run in both the positive and negative ionization modes allowing for the possible identification of compounds not yet in the library. The newly created library contains compound information, including product ion mass spectra, molecular weight, chemical structure, molecular formula, and CAS number. LOD was defined by the lowest concentration that provided a signal-to-noise ratio of at least 3 and a search index (SI) match of at least 600, while simultaneously providing a reverse search index (RSI) match of at least 700.
These default values were not changed prior to this research; however, the SI and RSI criteria can be raised either globally or on a compound by compound basis as laboratory procedures are developed. The individual index values are calculated by the ToxID software and serve as an indicator of the quality of the match between the unknown mass spectrum and the mass spectrum contained within the library. Spectrum quality was consistent throughout the concentration range investigated for each compound until the LOD was reached, at which time the spectral quality deteriorated to the point that a positive identification was not possible. This extensive amount of data has been tabulated and can be seen in Table I . Two different user-selectable report formats are produced by the ToxID software following sample analysis. The long version of the report produced a separate page for each compound in the specimen that matched the criteria described. This format included the acquired and library spectra, the spectrum difference, a chemical structure, a chromatogram, and all of the compound-specific information described. An example of this report format can be seen in Figure 1 . The short version of the report condensed all of the information for each drug present in the sample onto one page. This page included a chromatogram for each positive analyte and all of the compoundspecific information described. An example of this format can be seen in Figure 2 . The six compounds present in Figure 2 were chosen because they co-elute, and both positive and negative ionization were required to ionize these compounds. The detection of six co-eluting compounds that required both positive and negative ionization in one injection further exemplifies the robustness of the technique. There were interesting findings on both the MS and the extraction sides of this experiment. The linear ion trap is extremely sensitive and allowed for the identification of the majority of the compounds investigated at concentrations as low as 1 ng/mL. However, in a few instances, this methodology proved to be unsatisfactory. For example, certain compounds † All concentrations are presented with the units of ng/mL. ‡ Denotes the fraction from which the compound was recovered during the extraction process. If seen in significant quantities in both fractions, the proportion is given followed by (A) for the acid and (B) for the base fraction.
such as tramadol ionize exceptionally well, but the chemical structure does not allow for fragmentation of the precursor ion in the linear ion-trap under these specific conditions. The tramadol product ion and the precursor ion are identical, essentially eliminating the MS-MS spectra for each. As a result, the software could not differentiate between the precursor and product ions during analysis, preventing the identification of this compound when utilizing this methodology. Of the 369 compounds initially investigated, this phenomenon was encountered 6 times. The six compounds that could not be fragmented following precursor ionization were fosinopril, meclofenamic acid, phenylbutazone, tenoxicam, terbutaline, and tramadol. Another MS-related issue encountered during this work was compound ionization. Some compounds, under these specific mobile phase and MS conditions, would not ionize or ionized poorly. Without a precursor ion, there can be no product mass spectrum and therefore no compound identification. Of the 369 compounds initially investigated, this phenomenon was encountered 4 times. The four compounds that could not be ionized under these conditions were acamprosate, amiodarone, isosorbide, and simvastatin. The two limitations discussed preclude the use of this LC-MS methodology alone as a comprehensive GUS technique. However, it should be noted that only approximately 3% of the compounds initially investigated were not amenable with this technique. Ionization forming the precursor ion and subsequent fragmentation to form the product ion spectra allows for compound identification via library matching to a known spectrum. However, isolating the compounds contained within the library from a biological matrix and introducing these compounds into the MS is a complex process. As can be seen in the extraction section, the procedure used was comprehensive, lengthy, and labor intensive. An effort to isolate compounds from a wide variety of chemical classes sometimes prevents the ability to detect specific drugs at low levels. Additionally, some compounds were detected in both the basic and the acidic fractions following extraction. Clonazepam, for example, was found to have an LOD of 10 ng/mL in the basic fraction. However, only 60% of the total number of area counts for this compound was seen in the basic fraction. Forty percent of the initial concentration was seen in the acidic fraction. If 100% of the dose was contained within either fraction, the LOD obtained would inevitably be lower. This phenomenon was observed with four of the compounds investigated, including clonazepam, tetrahydrocannabinol, irbesartan, and ramipril. A possible solution to this problem would be to eliminate, or significantly simplify, the extraction procedure. In the near future we plan to investigate a simple "crash-and-shoot" extraction process. In this procedure, acetonitrile would be added to a biological specimen to precipitate any proteins present. The sample would then be centrifuged, and a small portion of the acetonitrile would be injected into the LC-MS-MS system. This procedure may improve extraction efficiency for many of the compounds currently in the library. We are hopeful that the crash-and-shoot methodology will allow for less sample volume to be used while achieving similar LOD results as limited specimen volumes can be encountered during forensic work.
The newly validated library developed with LC-MS-MS technology has been in use as a research tool for the previous 12 months. Over this time period, prior to injection on our currently used LC-UV system, a small portion of each extract was removed and injected onto the LC-MS-MS system so that a direct comparison of the results would be possible. It became immediately evident that the new analytical methodology would be more sensitive than the currently used technique. Numerous compounds that may not have been detected by the current LC-UV and GC-MS combination have been confirmed after screening positive by LC-MS-MS. This encouraging result provides more evidence in favor of a fundamental shift in the analytical techniques used for the purpose of specimen screening.
Conclusions
A compound library constructed with spectra obtained from an ion-trap LC-MS-MS for 359 forensically important compounds has been created. This methodology has the potential to replace current LC-UV techniques and allow for the detection of compounds at lower concentrations than previously possible. The LOD for each compound in the library has been established, as well as the fraction in which the compound will be seen following extraction. The future addition of additional compounds is a relatively simple procedure as standards for new pharmaceutical compounds are obtained. An additional benefit is the collection of full-scan MS data in both the positive and negative ionization modes throughout the run. These data provide the molecular weight of any compound encountered that is not currently in the library, which could be useful for unknown identification. When combined with our current GC-MS procedure, the newly validated LC-MS screening technique will allow for the detection of more compounds at lower concentrations than is currently possible. 
